Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com
by Michael Walen · The Markets DailyStockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Up 2.2 %
NASDAQ:AKTX opened at $1.41 on Friday. The business’s 50 day moving average is $1.51 and its two-hundred day moving average is $2.65. Akari Therapeutics has a 52 week low of $0.90 and a 52 week high of $4.40.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Recommended Stories
- Five stocks we like better than Akari Therapeutics
- Roth IRA Calculator: Calculate Your Potential Returns
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- What Are Dividend Challengers?
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac